Landscapes / Companies
Marker Therapeutics, Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 1
Drugs
2
in active trials · 5 in all
Trials
3 active
6 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1 | 28 Feb 2028Phase 1 trial completes | |||
| Next date | 28 Feb 2028 · Phase 1 trial completes | ||||
| Also tested for | Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory and 8 more | ||||
| Open drug page | |||||
— |
Phase 1 | Sep 2029Phase 1 trial completes | |||
| Next date | Sep 2029 · Phase 1 trial completes | ||||
| Also tested for | Acute Myeloid Leukemia, in Relapse, MDS | ||||
| Open drug page | |||||
About
- No active trial
- FRα peptide, FRα vaccine, MT-401
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021